Current best clinical practices for monitoring of interstitial lung disease

Expert Rev Respir Med. 2022 Dec 26. doi: 10.1080/17476348.2022.2162504. Online ahead of print.

ABSTRACT

INTRODUCTION: Interstitial lung diseases (ILDs) are a heterogeneous group of inflammatory and/or fibrotic conditions with variable outcome and often a dismal prognosis. Since many ILDs are progressive in nature, monitoring of signs and symptoms of progression is essential to inform treatment decisions and patient counseling. Monitoring of ILDs is a multimodality process and includes all aspects of the disease e.g., measurement of pulmonary function and exercise capacity, symptom registration and quality of life (QoL), imaging, comorbidities and/or involvement of other organs to assess disease activity, symptom burden, treatment effects, adverse events, the need for supportive and palliative care, and lung transplantation.

AREAS COVERED: For this narrative review, we searched the PUBMED database to identify articles relevant for monitoring ILDs, including pulmonary function tests, exercise capacity, imaging, telemedicine, symptoms and QoL.

EXPERT OPINION: Due to the high heterogeneity of the ILDs and their disease course, an individualized multimodality approach must be applied. There is no evidence for the optimal interval of monitoring.Future strategies include use of telemedicine for home monitoring of lung function and symptoms, use of artificial intelligence to support automatized guidance of patients, computerized evaluation of ILD changes on imaging, and new imaging tools with less radiation dosage.

PMID:36572644 | DOI:10.1080/17476348.2022.2162504